clinical trial · NCT05661201
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Georgetown University·phase1·recruiting·n = 24
Solid TumorKRAS Mutation-Related TumorsNEROFEDoxorubicin
brief summary
The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin. Participants will receive weekly doses of NEROFE and doxorubicin.
started
Apr 12, 2023
primary completion
Jan 1, 2027
completion
Jan 1, 2027
last updated
Mar 6, 2026
official title
Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol